Literature DB >> 33409883

Rates of Metformin Use in Stage 3b Chronic Kidney Disease Rose After FDA Label Change.

Alex Huang1, Xian Wu1, Jeremy Orloff1,2, Jea Young Min1, James Flory3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33409883      PMCID： PMC8481432          DOI： 10.1007/s11606-020-06380-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   6.473


× No keyword cloud information.
  3 in total

1.  Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Kunihiro Matsushita; Elizabeth Selvin; Lori D Bash; Brad C Astor; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2010-02-26       Impact factor: 8.860

2.  Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience.

Authors:  Kasia J Lipska; James H Flory; Sean Hennessy; Silvio E Inzucchi
Journal:  Circulation       Date:  2016-11-01       Impact factor: 29.690

Review 3.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.